Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary.
Pharmacology. 2012;89(3-4):179-87. doi: 10.1159/000336872. Epub 2012 Mar 16.
Given the vast therapeutic potential of the endocannabinoid system, the revelation of a novel cannabinoid-sensitive target was treated with great excitement. The orphan G-protein coupled receptor 55 (GPR55) was initially touted as a novel cannabinoid target in early industrial patent literature. Consequently, numerous studies have revealed GPR55 expression in a diverse array of cells and tissues, regulating various physiological and pathological processes. Although a confusing cannabinoid profile has prevented its classification as a cannabinoid receptor, the therapeutic potential of the receptor cannot be denied, with roles in cancer progression, bone resorption and analgesia. This commentary aims to summarize GPR55 expression data and speculate on potential therapeutic exploitation of this enigmatic orphan receptor.
鉴于内源性大麻素系统具有巨大的治疗潜力,因此新发现的大麻素敏感靶点的出现令人兴奋。孤儿 G 蛋白偶联受体 55(GPR55)最初在早期工业专利文献中被吹捧为一种新的大麻素靶点。因此,许多研究已经揭示了 GPR55 在各种细胞和组织中的表达,调节各种生理和病理过程。尽管其大麻素特征混乱,阻止了其被分类为大麻素受体,但该受体的治疗潜力不容忽视,它在癌症进展、骨吸收和镇痛方面发挥作用。本评论旨在总结 GPR55 的表达数据,并推测对这个神秘的孤儿受体进行潜在的治疗性开发。